Executives from Scynexis are launching their road show today in hopes of generating Wall Street demand for its shares in an initial public offering. The company reaffirms it hopes to sell shares at $12 to $14.

The company made the road show official with an announcement Monday morning.

Scynexis is looking to sell just over 4.2 million shares.

Underwriters have an option to purchase another 634,620 shares at the IPO price less an underwriting discount.

“RBC Capital Markets and Canaccord Genuity are serving as joint bookrunning managers,” the company said. “In addition, JMP Securities is participating as lead manager in the offering. The offering of SCYNEXIS common stock will be made only by means of a prospectus. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.”

In a new securities filing last Wednesday, Scynexis is targeting the sale of 4.2 million shares of stock at between $12 and $14 per share with a goal of raising up to $68.1 million. Scynexis would have purportedly 15.7 million shares outstanding after an IPO.

The Durham drug-development company doesn’t yet have a drug on the market. The company had $1.4 million in cash as of Dec. 31, according to reports, and has earmarked $15 million of the proceeds from an IPO to pay down a loan.

Some of the privately-held company’s shareholders remain interested in purchasing up to $4 million worth of IPO shares and French pharmaceutical company Sanofi (currently a 6 percent owner of Scynexis) is interested in purchasing up to $5 million, according to the filing.

Scynexis is a pharmaceutical committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Their lead product candidate, SCY-078, is deemed by the company as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. They also have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases.

Scynexis originally partnered with drug giant Merck in 2002 to develop and commercialize SCY-078. Merck chose to return it to Scynexis last year.

According to filings, Scynexis generated $16.9 million in revenue last year from performing R&D services for other companies with a net loss in 2013 recorded at $30.5 million.

If the IPO is successful, Scynexis would join a growing number of Triangle firms – especially biotechs – that have gone public in the last year. (Check out WRALTechWire’s IPO Watch report.)